The rebound hypertension in mice that occurs after withdrawal of clonidine, an α1D, α2A-C adrenergic receptor agonist, is mitigated by an increase in nitric oxide bioavailability, an effect that is prevented by suppression of GRK2 activity [42]. The gene discussed is GRK2; the disease is hypertensive disorder.